Amphastar Gains FDA OTC Approval for Rextovy 4mg Naloxone Nasal Spray in Opioid Overdose

A second OTC naloxone nasal spray now carries FDA nonprescription approval, and for Amphastar Pharmaceuticals the clearance of Rextovy immediately raises the operational question of whether manufacturing capacity, quality systems, and supply-chain infrastructure are positioned for consumer-market volumes. The agency granted approval on June 16, 2026, authorising the 4 mg naloxone hydrochloride formulation for sale in pharmacies, convenience stores, and online channels without a prescription.

The approval follows the first OTC naloxone nasal spray cleared in 2023 and enters a market where overdose mortality, while declining, remains a significant public health burden. Provisional CDC data cited by FDA show a 12-month overdose death count of 111,451 through August 2023, falling to 68,632 through December 2025, with illicit fentanyl remaining the primary driver. FDA's Acting CDER Director Mike Davis, M.D., Ph.D., noted that multiple approved OTC formulations expand access, encourage cost competition, and create alternative sourcing options.

For plant heads and QA directors at Amphastar, the shift from prescription to nonprescription distribution introduces a distinct set of 21 CFR Part 211 considerations: batch scale, packaging line throughput, and consumer-facing labelling compliance all require re-evaluation under OTC conditions. Rextovy's approved packaging includes pictorial five-step directions and a 911 call instruction after the first dose, meaning label control and print verification become critical quality checkpoints at release.

Regulatory affairs leads should note that FDA's Office of Nonprescription Drug Products has signalled openness to additional entrants, with Director Karen Murry, M.D., explicitly inviting manufacturers seeking nonprescription naloxone market access to contact the agency. That posture suggests the competitive landscape could expand further, compressing timelines for any manufacturer already in development. Process validation packages and sterility assurance data for nasal spray formats will face the same evidentiary bar regardless of when a subsequent applicant engages.

The approval aligns with the federal Great American Recovery Initiative, which coordinates government-wide addiction and substance use disorder response, adding a policy dimension that may sustain regulatory prioritisation of naloxone access applications in the near term.

Amphastar's ability to meet sustained OTC demand at competitive cost will depend on how quickly validated commercial-scale processes can be confirmed and supply agreements secured across the retail and online distribution channels now authorised under the approval.

Source: FDA Press Releases RSS Feed via fda.gov, June 16, 2026.